Phase I study of niraparib with radiotherapy for treatment of metastatic and locally advanced invasive carcinoma of the cervix (NIVIX)
Concurrent niraparib 100 mg with pelvic radiotherapy was feasible without protocol-defined DLTs. Treatment-limiting grade 2 thrombocytopenia occurred in patients with identifiable risk factors including low baseline platelet counts, hepatic dysfunction, and low body weight. These hypothesis-generating findings support further investigation with attention to patient selection criteria in future trials combining PARP inhibitors with radiotherapy.
Authors
- Alfredo Echeverria
- Jan Sunde (ORCID: https://orcid.org/0000-0001-9855-2484)
- Anthony B. Costales (ORCID: https://orcid.org/0000-0003-4326-9782)
- Shelly Sharma (ORCID: https://orcid.org/0000-0002-2776-0814)
- Michelle Ludwig (ORCID: https://orcid.org/0000-0001-8860-7269)
- T.R. Hall (ORCID: https://orcid.org/0000-0002-3913-4079)
- Eunji Jo (ORCID: https://orcid.org/0000-0002-6432-3058)
- Piyush Pathak (ORCID: https://orcid.org/0000-0001-9775-827X)
- S. G. Hilsenbeck
- Claire Hoppenot
- Matthew L. Anderson
Institutions
- Baylor College of Medicine (US)
- University of South Florida (US)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2026-03-09
- DOI
- https://doi.org/10.3389/fonc.2026.1677424
- Primary Topic
- PARP inhibition in cancer therapy
- Type
- article
- Field-Weighted Citation Impact
- 0.00